2016-11-11T10:40:11-06:00 2015-12-31 KPMG LLP 345 Park Avenue New York NY 101540102 990 2015-01-01 800631734 NEW YORK GENOME CENTER INC % CHRISTOPHER DUIGNAN NEWY 6469777000 101 AVENUE OF THE AMERICAS NEW YORK NY 10013 CHRIS DUIGNAN vp finance 6469777000 2016-11-09 true DEVIN L DUNCAN P01249521 2127589700 2016-11-07 2015 2017-02-10 21:41:12Z Robert B Darnell MD PhD 101 AVENUE OF THE AMERICAS NEW YORK NY 10013 80701142 false X www.nygenome.org X 2010 DE ESTABLISH A STATE-OF-THE-ART, WORLD CLASS GENOME SEQUENCING, BIOINFORMATICS, AND RESEARCH CENTER IN NEW YORK CITY. FOR MORE INFORMATION SEE SCHEDULE O. 27 26 191 27 194009 -50372 52034400 61060764 7379559 17719082 18460 840757 504146 182495 59936565 79803098 0 27788 0 0 16526784 22326706 557494 1450 1055562 40651482 53944287 57735760 76300231 2200805 3502867 114312997 110178881 112478799 104841816 1834198 5337065 X establish a state-of-the-art, world class genome sequencing, bioinformatics, and research center in new york city. for more information see schedule o. false false 41154448 17160866 RESEARCH SEQUENCING - THE NEW YORK GENOME CENTER, INC (NYGC). STARTED ITS RESEARCH SEQUENCING SERVICES IN 2012 WITH FIVE SEQUENCING MACHINES IN A TEMPORARY PILOT LAB SPACE. IN 2013, THE CENTER OPENED ITS HEADQUARTERS AT 101 AVENUE OF THE AMERICAS IN NEW YORK CITY. FOR MORE INFORMATION, SEE SCHEDULE O. 9022027 27788 RESEARCH - NEW YORK GENOME CENTER CONDUCTS INNOVATIVE RESEARCH AND METHODS DEVELOPMENT AND IMPROVEMENT. SEVERAL KEY AREAS OF DISEASE FOCUS INCLUDE CANCER, AUTOIMMUNE DISEASE AND NEUROLOGICAL DISORDERS. IN SUPPORT OF THE LATTER, NYGC'S CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND) IS DEDICATED TO STUDYING NEURODEGENERATIVE DISEASES SUCH AS ALS AND ALZHEIMER'S. THE CGND'S PARTNERS INCLUDE OUR IFMS, THE PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA, THE NORTHEAST ALS CONSORTIUM, MASSachusetts GENERAL HOSPITAL/HARVARD MEDICAL SCHOOL AND UMASS MEDICAL SCHOOL. FOR MORE INFORMATION, SEE SCHEDULE O. 2146761 364207 CLINICAL SEQUENCING - NYGC maintains A CLIA (CLINICAL LABORATORY IMPROVEMENT AMENDMENTS)LAB WHICH OFFERs NEXT GENERATION SEQUENCING (NGS) BASED TESTING THAT can BE USED TO VALIDATE CLINICALLY SIGNIFICANT RESEARCH FINDINGS FOR RARE DISEASES, CANCER, AND OTHER CLINICALLY RELEVANT DIAGNOSTIC SERVICES OR AS MAY BE PRESCRIBED BY PHYSICIANS ON BEHALF OF THEIR PATIENTS. IN MARCH 2015, NYGC RECEIVED NOTICE OF ACCEPTANCE FROM THE NEW YORK STATE DEPARTMENT OF HEALTH FOR OUR NEXT GENERATION SEQUENCING-BASED METHOD FOR WHOLE EXOME ANALYSIS FOR CONSTITUTIONAL DISORDERS. applications for approval of additional tests are pending with the new york state department of health. 52323236 true true false true false false false false false false true false false true true true true false false false false false false false false false false true false true false false false false false false false false false false false false false false false false false true 61 0 true 191 true true true false false false false false false false false false X 27 26 false false false false true true true true true false false true true true true true true true true true true CT NJ NY X CHRISTOPHER DUIGNAN 6469777000 101 AVENUE OF THE AMERICAS 7TH FLO NEW YORK NY 10013 X DAFNA BAR-SAGI PHD DIRECTOR 1.0 0.0 X 0 0 0 RUSSELL L CARSON MBA DIRECTOR & CO-CHAIR 4.0 0.0 X X 0 0 0 DENNIS S CHARNEY MD DIRECTOR 1.0 0.0 X 0 0 0 ROBERT B DARNELL MD PHD FOUNDING DIRECTOR AND CEO 10.0 0.0 X X 318474 0 0 NICHOLAS DONOFRIO DIRECTOR 1.0 0.0 X 0 0 0 JOHN B EHRENKRANZ DIRECTOR 1.0 0.0 X 0 0 0 ANTHONY E EVNIN PHD DIRECTOR 1.0 0.0 X 0 0 0 WILLIAM E FORD DIRECTOR 1.0 0.0 X 0 0 0 LAURIE H GLIMCHER MD DIRECTOR 1.0 0.0 X 0 0 0 LEE GOLDMAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 JOHN HAVENS DIRECTOR / COMMITTEE CHAIR 1.0 0.0 X 0 0 0 WESLIE R JANEWAY DIRECTOR 1.0 0.0 X 0 0 0 EDISON T LIU MD DIRECTOR 1.0 0.0 X 0 0 0 TOM MANIATIS PHD DIRECTOR 1.0 0.0 X 0 0 0 HERBERT PARDES MD DIRECTOR 1.0 0.0 X 0 0 0 FRANK RICHARDSON JD DIRECTOR 1.0 0.0 X 0 0 0 ARTHUR J SAMBERG DIRECTOR 1.0 0.0 X 0 0 0 IVAN G SEIDENBERG MBA DIRECTOR & CO-CHAIR 4.0 0.0 X X 0 0 0 FRANK V SICA DIRECTOR 1.0 0.0 X 0 0 0 JAMES SIMONS PHD DIRECTOR 1.0 0.0 X 0 0 0 STEVEN SINGER ESQ DIRECTOR 1.0 0.0 X 0 0 0 ALLEN M SPIEGEL MD DIRECTOR 1.0 0.0 X 0 0 0 SAMUEL L STANLEY JR MD DIRECTOR 1.0 0.0 X 0 0 0 BRUCE STILLMAN PHD DIRECTOR 1.0 0.0 X 0 0 0 MARC TESSIER-LAVIGNE PHD DIRECTOR 1.0 0.0 X 0 0 0 CRAIG B THOMPSON MD DIRECTOR 1.0 0.0 X 0 0 0 KEVIN J TRACEY MD DIRECTOR 1.0 0.0 X 0 0 0 CHRIS DUIGNAN VP, FINANCE 40.0 0.0 X 296107 0 43040 ANDREA ARMSTRONG CHIEF HR OFFICER & VP, ADMIN. 40.0 0.0 X 434500 0 13367 CAROL ASHE CHIEF BUSINESS OFFICER 40.0 0.0 X 513333 0 21674 TOBY BLOOM DEPUTY SCIENTIFIC DIRECTOR 40.0 0.0 X 344582 0 35645 MATTHEW J PELO VP FIN STRATEGY & OPS 40.0 0.0 X 301583 0 21674 HAROLD SWERDLOW VICE PRESIDENT OF SEQUENCING 40.0 0.0 X 454896 0 29857 KATHLEEN MCGOVERN KEARNS VP, DEVELOPMENT & COMM 40.0 0.0 X 312585 0 27623 SHAILAJA GARGEYA SR. DIR. SOFTWARE ENGINEERING 40.0 0.0 X 276217 0 25085 SOREN GERMER SCI DIR, SEQUENCING OPS 40.0 0.0 X 201747 0 28449 DAYNA M OSCHWALD SNR DIR, INFO PGM MGMT 40.0 0.0 X 218312 0 25857 NATHANIEL PEARSON SNR DIR,SCITFC ENGMT & PUB OTR 40.0 0.0 X 204667 0 18584 JULIA LOUISE MOORE VOGEL DIRECTOR, OFFICE OF THE CEO 40.0 0.0 X 182445 0 18827 SAMUEL SERVELLO DEPUTY GENERAL COUNSEL 40.0 0.0 X 297679 0 22382 SARAH AVINS VP,EXT AFR & CHIEF DEV OFFICER 0.0 0.0 X 112056 0 11480 4469183 0 343544 73 true true false American Int'l Relocation Solution PO Box 536459 PITTSBURGH PA 15253 relocation services 363294 Computer Design Integration LLC 696 Route 46 West TETERBORO NJ 07608 IT services 393020 Daniel Petri 2 Hergenhan Court BEDFORD NY 10506 Advisory Services 403536 Moses Singer LLP 405 Lexington Avenue NEW YORK NY 10174 legal services 365692 Robert Darnell MD PHD 236 Elderwood Ave PELHAM NY 10803 management services 318474 15 1535000 25855254 33670510 61060764 RESEARCH SEQUENCING 541700 17354875 17160866 194009 CLINICAL SEQUENCING 541700 364207 364207 17719082 16595 16595 0 0 252206 252206 0 0 0 1470000 645838 824162 824162 824162 0 0 0 IT SERVICE REVENUE 900099 65625 65625 EVENT SPACE REVENUE 900099 61204 61204 SPONSORSHIP REVENUE 900099 53948 53948 1718 1718 182495 79803098 17590698 194009 957627 27788 27788 0 0 0 3168940 864980 1963752 340208 0 15255995 11047628 3939737 268630 763121 519791 219546 23784 1786393 1223067 528351 34975 1352257 947736 367332 37189 0 861901 861901 196546 196546 90000 90000 1450 1450 0 2626152 2073475 543804 8873 1266109 1266109 1043458 340655 701579 1224 2368450 424289 1940786 3375 0 13441041 10194031 3017977 229033 502919 201088 294109 7722 0 76868 49507 24352 3009 2200749 1601475 567077 32197 0 13180739 8068017 5062091 50631 354872 354872 RECRUITMENT 722022 722022 DIRECT COST OF SEQUENCING 12801877 12801877 EVENTS 219560 219560 RESEARCH & CLIA 1827174 1827174 163850 110658 39930 13262 76300231 52323236 22921433 1055562 10359114 8314331 0 0 9307378 7904830 2949753 4256171 0 0 0 0 0 0 2176154 6724235 4948317 4607181 96055430 28752074 73520094 67303356 0 0 0 0 0 0 0 0 11052187 11068777 114312997 110178881 7520828 5194484 0 0 770605 7050115 0 0 0 0 0 0 10153237 6411955 64999000 54999000 29035129 31186262 112478799 104841816 X -7680230 -5804618 9514428 11141683 0 0 1834198 5337065 114312997 110178881 3502867 X false true X true false X 19728681 19649601 14419687 52034400 61060764 166893133 0 0 19728681 19649601 14419687 52034400 61060764 166893133 63969810 102923323 24896 83412 556550 268801 933659 22767 43718 66485 116870 116870 168010147 30144649 0.61260 0.00000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false false false true 90000 90000 false false LOBBYING ACTIVITIES PART II-B, LINE 1I through its legislative consultant, nygc advocated for government funds to support current operations and/or establish a foundation for expanding research opportunities at the New York Genome Center. The activities include, and are not limited, to New York State and New York City Governments. 53349697 6477431 46872266 41226167 21932921 19293246 1479566 341722 1137844 67303356 SECURITY DEPOSITS 11068777 11068777 0 ACCRUED INTEREST PAYABLE 4201438 DEFERRED RENT 26984824 31186262 X 80083668 28364 28364 80055304 -252206 -252206 79803098 76580801 28364 252206 280570 76300231 76300231 INCOME TAXES PART X, LINE 2 THE CENTER IS SUBJECT TO THE PROVISIONS OF FASB ASC 740-10-05, INCOME TAXES- OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. THE CENTER RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2015 AND 2014. REVENUE AND EXPENSE RECONCILIATION PART XI, LINE 4B AND PART XII, LINE 2D $252,206 - RENTAL EXPENSES ALLOCABLE TO 990, PART VIII true TRUSTEES OF COLUMBIA UNIV IN CITY OF NY 1130 ST NICHOLAS AVE NEW YORK NY 10032 135598093 501(C)(3) 27788 RESEARCH SUBAWARD 1 Monitoring use of grant funds schedule i, part i, line 2 NYGC MONITORS SUBRECIPIENTS' USE OF GRANT FUNDS IN MULTIPLE STAGES. IN THE PRE-AWARD PHASE, SUBRECIPIENTS ARE EVALUATED BY NYGC'S SPONSORED RESEARCH AND ACADEMIC/SCIENTIFIC DEPARTMENTS, WITH CONSIDERATION OF SUBRECIPIENT CAPABILITIES AND INFRASTRUCTURE, AS WELL AS THE APPROPRIATE CHECKS FOR SUSPENSION AND DEBARMENT. IN THE POST-AWARD PHASE, NYGC'S SPONSORED RESEARCH TEAM MONITORS PROGRAMMATIC PROGRESS (IN COORDINATION WITH ANY INTERNAL SCIENTIFIC PERSONNEL) IN A MANNER CONSISTENT WITH THE TERMS AND CONDITIONS OF THE AWARD. NYGC'S FINANCE/GRANTS ACCOUNTING DEPARTMENT REVIEWS ANY SUBRECIPIENT EXPENSES INVOICED TO NYGC FOR ALLOWABILITY WITH REGARDS TO RELEVANT COST PRINCIPLES AND BUDGETARY RESTRICTIONS, AND PROVIDES SUBRECIPIENT INVOICES TO SPONSORED RESEARCH FOR THEIR REVIEW AND APPROVAL. ONCE SPONSORED RESEARCH AND FINANCE DEPARTMENTS HAVE APPROVED SUBRECIPIENT INVOICES, THE SUBRECIPIENT IS PAID. SUBAWARDS ELIGIBLE FOR FFATA REPORTING ARE RECORDED IN THE FSRS (THE FFATA SUBAWARD REPORTING SYSTEM) IN ACCORDANCE WITH THE FEDERAL REPORTING REQUIREMENTS OF FIRST-TIER SUBAWARDS UNDER NYGC'S PRIME FEDERAL AWARDS. X X true true X X X false false false false false false false true false ANDREA ARMSTRONG CHIEF HR OFFICER & VP, ADMIN. 410500 0 24000 0 0 0 13250 0 117 0 447867 0 0 0 CAROL ASHE CHIEF BUSINESS OFFICER 409333 0 104000 0 0 0 13250 0 8424 0 535007 0 0 0 TOBY BLOOM DEPUTY SCIENTIFIC DIRECTOR 344582 0 0 0 0 0 13250 0 22395 0 380227 0 0 0 ROBERT B DARNELL MD PHD FOUNDING DIRECTOR AND CEO 314650 0 0 0 3824 0 0 0 0 0 318474 0 0 0 CHRIS DUIGNAN VP, FINANCE 296107 0 0 0 0 0 12280 0 30760 0 339147 0 0 0 SHAILAJA GARGEYA SR. DIR. SOFTWARE ENGINEERING 276217 0 0 0 0 0 13250 0 11835 0 301302 0 0 0 SOREN GERMER SCI DIR, SEQUENCING OPS 191747 0 10000 0 0 0 10268 0 18181 0 230196 0 0 0 DAYNA M OSCHWALD SNR DIR, INFO PGM MGMT 218312 0 0 0 0 0 7676 0 18181 0 244169 0 0 0 MATTHEW J PELO VP FIN STRATEGY & OPS 301583 0 0 0 0 0 13250 0 8424 0 323257 0 0 0 SAMUEL SERVELLO DEPUTY GENERAL COUNSEL 294166 0 0 0 3513 0 13250 0 9132 0 320061 0 0 0 HAROLD SWERDLOW VICE PRESIDENT OF SEQUENCING 403151 0 25000 0 26745 0 13250 0 16607 0 484753 0 0 0 KATHLEEN MCGOVERN KEARNS VP, DEVELOPMENT & COMM 312585 0 0 0 0 0 10833 0 16790 0 340208 0 0 0 NATHANIEL PEARSON SNR DIR,SCITFC ENGMT & PUB OTR 204667 0 0 0 0 0 10160 0 8424 0 223251 0 0 0 JULIA LOUISE MOORE VOGEL DIRECTOR, OFFICE OF THE CEO 162445 0 20000 0 0 0 9167 0 9660 0 201272 0 0 0 SARAH AVINS VP,EXT AFR & CHIEF DEV OFFICER 97278 0 0 0 14778 0 5662 0 5818 0 123536 0 0 0 TAX INDEMNIFICATION AND GROSS-UP PAYMENTS PART I, LINE 1 NYGC PROVIDED RELOCATION SERVICES FOR THE FOLLOWING EMPLOYEE HIRED FROM OUTSIDE OF NEW YORK CITY: HAROLD SWERDLOW. THE VALUE OF THESE RELOCATION SERVICES IS CONSIDERED COMPENSATION TO THE EMPLOYEE FOR WHICH NYGC MAKES GROSS-UP PAYMENTS TO ALLEVIATE THE TAX BURDEN ON THE EMPLOYEE. PERSONAL SERVICES PART I, LINE 1 NYGC PROVIDED PERSONAL SERVICES INCLUDING TAX ASSISTANCE AND WILL PREPARATION TO ROBERT DARNELL. EXECUTIVE COMPENSATION PART I, LINE 3 IN 2012, THE BOARD APPROVED Robert DARNELL'S COnsulting fee; IN 2015, THE EXECUTIVE COMPENSATION COMMITTEE APPROVED Robert DARNELL'S INCREASE to his consulting fee. NON-FIXED PAYMENTS SCHEDULE J, PART I, LINE 7 & PART II, COLUMN B(II) THE FOLLOWING EMPLOYEES RECEIVED NON-FIXED PAYMENTS IN 2015: ANDREA ARMSTRONG, SOREN GERMER, AND JULIA LOUISE MOORE VOGEL. The Organization's Mission Form 990, Part I, Line 1 & Part III, Line 1: NEW YORK GENOME CENTER, INC. IS ORGANIZED AND SHALL BE OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION WHOSE MEMBERS SHALL INCLUDE LEADING ACADEMIC, MEDICAL, AND RESEARCH INSTITUTIONS FOR THE PURPOSE OF ESTABLISHING A STATE-OF-THE- ART, WORLD CLASS GENOME SEQUENCING, BIOINFORMATICS AND RESEARCH CENTER IN NEW YORK CITY, WITH THE FOLLOWING KEY OBJECTIVES: (I) CREATING AN INTELLECTUALLY VIBRANT COLLABORATION AMONGST THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY; (II) RECRUITING WORLD CLASS SCIENTIFIC LEADERSHIP TO DIRECT THE SCIENTIFIC DEVELOPMENT OF THE CORPORATION, TOGETHER WITH THE MEMBERS OF THE CORPORATION; (III) OBTAINING COMMITMENTS FROM THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO AFFILIATE WITH AND USE SERVICES PROVIDED BY THE CORPORATION; (IV) PROVIDING SEQUENCING AND BIOINFORMATICS SERVICES TO THE ACADEMIC AND SCIENTIFIC COMMUNITIES, INCLUDING THE INSTITUTIONAL FOUNDING MEMBERS; (V) DEVELOPING ADVANCED BIOINFORMATICS CAPABILITIES BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE CORPORATION'S FACILITIES; (VI) ADVANCING THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES AND THERAPEUTICS TO TREAT HUMAN DISEASE; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; AND (VIII) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. PROGRAM SERVICE ACCOMPLISHMENT - SEQUENCING FORM 990, PART III, LINE 4A: THE NEW YORK GENOME CENTER, INC. STARTED ITS RESEARCH SEQUENCING SERVICES IN 2012 WITH FIVE SEQUENCING MACHINES IN A TEMPORARY PILOT LAB SPACE. IN 2013, THE CENTER OPENED ITS HEADQUARTERS AT 101 AVENUE OF THE AMERICAS IN NEW YORK CITY. THE NEW FACILITY INCLUDES: 30,000 SQUARE FEET OF SEQUENCING LAB SPACE; SERVING AS A STATE OF THE ART SEQUENCING CENTER TO THE ACADEMIC AND SCIENTIFIC COMMUNITIES IN NEW YORK CITY TO AID THEM IN RESEARCH, INCLUDING COLLABORATIVE RESEARCH WITH THE CENTER, TO ADVANCE THE DEVELOPMENT OF NEW TREATMENTS, THERAPIES, AND THERAPEUTICS TO TREAT HUMAN DISEASE A DEDICATED OPEN-PLAN BIOINFORMATICS FLOOR TO ENCOURAGE DISCUSSION AND COLLABORATION AMONG RESEARCHERS AND SCIENTISTS A DATA STORAGE ANNEX TO SAFELY STORE THE IMMENSE AMOUNTS OF DATA PRODUCED AND FACILITATE RESEARCH STUDIES ACROSS A LARGE NUMBER OF PEOPLE TRANSLATIONAL RESEARCH LABS WITH SPACE TO HOST A NUMBER OF PRINCIPAL INVESTIGATORS AND THEIR TEAMS FROM VARIOUS MEMBER INSTITUTIONS AN INNOVATION LAB TO TEST AND EVALUATE NEW SEQUENCING TECHNOLOGIES A CLIA LAB TO SERVICE CLINICAL LABORATORY TESTING NEEDS In 2014, nygc purchased the Illumina HiSeq X ten system. NYGC is the only institution in the Tri-State Area to acquire the HiSeq X Ten, the fastest and most advanced sequencing technology available. AT DECEMBER 31, 2015, NYGC'S FACILITY CONTAINED 14 ILLUMINA HISEQ X INSTRUMENTS TO ENABLE SEQUENCING OF UP TO 25,000 30X HUMAN WHOLE GENOMES OR 6,250 TUMOR/NORMAL PAIRS AT 80X/40X EACH YEAR, AND 12 ILLUMINA HISEQ 2500S TO ALLOW ANNUAL SEQUENCING OF TENS OF THOUSANDS OF WHOLE EXOME, RNA, METHYLATION, OR CUSTOM SAMPLES. SEQUENCING IS A LABORATORY PROCESS THAT DETERMINES THE COMPLETE DNA SEQUENCE OF AN ORGANISM'S GENOME AT A SINGLE TIME. A SINGLE HUMAN GENOME YIELDS APPROXIMATELY 250 GIGABYTES OF DATA. THIS DATA IS THEN COMPUTATIONALLY ANALYZED TO INTERPRET THE SEQUENCE ACCORDING TO THE CLINICAL CONTEXT AND PROJECT SCOPE. BIOINFORMATICS IS A BRANCH OF BIOLOGICAL SCIENCE WHICH DEALS WITH ANALYZING BIOLOGICAL DATA AND EXPRESSING IT GRAPHICALLY USING SPECIALIZED SOFTWARE AND COMPUTATIONAL METHODS. BIOINFORMATICS IS USED TO DETECT AND ANALYZE GENOMIC VARIATIONS. IN HUMANS, GENETIC VARIATION CAN HAVE MEDICAL CONSEQUENCES AFFECTING DISEASE SUSCEPTIBILITY, INCLUDING PREDISPOSITION TO A WIDE ARRAY OF GENETIC DISEASES SUCH AS CANCER, DIABETES, CARDIOVASCULAR DISEASE, AUTISM, AND ALZHEIMER'S DISEASE. THEY CAN ALSO AFFECT AN INDIVIDUAL'S RESPONSE TO CERTAIN DRUG TREATMENTS, CAUSING THEM TO RESPOND WELL, NOT RESPOND AT ALL, OR EXPERIENCE ADVERSE SIDE EFFECTS. PROGRAM SERVICE ACCOMPLISHMENT - RESEARCH FORM 990, PART III, LINE 4b: New York Genome Center conducts innovative research and methods development and improvement. Several key areas of disease focus include cancer, autoimmune disease and neurological disorders. In support of the latter, NYGC's Center for Genomics of Neurodegenerative Disease (CGND) is dedicated to studying neurodegenerative diseases such as ALS and Alzheimer's. The CGND's partners include our IFMs, the Perelman School of Medicine at the University of Pennsylvania, the Northeast ALS Consortium, Mass General Hospital/Harvard Medical School and UMass Medical School. In addition to the CGND, NYGC has initiated several collaborative clinical studies, including those focused on rheumatoid arthritis and pediatric leukemia and neuroblastoma. NYGC also launched a multiinstitutional trial in which we are partnering with IBM to explore whether their Watson artificial intelligence technology can help create personalized treatments for patients with glioblastoma, a deadly form of brain cancer. NYGC's faculty members, most of whom hold a joint appointment at a Member Institution, are leading complementary research in areas including schizophrenia, population genomics, evolutionary mechanisms and disease risk, single cell genomics, and more. NYGC also has an Innovation Lab dedicated to protocol development, equipment evaluation, and informatics tool development and integration. ORGANIZATION MEMBERS FORM 990, PART VI, SECTION A, LINE 6: THERE ARE FOUR (4) CATEGORIES OF MEMBERS OF THE CENTER: INSTITUTIONAL FOUNDING MEMBERS, ASSOCIATE MEMBERS, PHARMAceutical/TECHNOLOGY MEMBERS AND OTHER MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS OF THE CENTER ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICAL COLLEGE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, (8) NORTHWELL HEALTH (F.K.A. NORTH SHORE LONG ISLAND JEWISH HEALTH SYSTEM), (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) Albert Einstein School of Medicine of Yeshiva University *ASSOCIATE MEMBERS: (1) American Museum of Natural History (2) Hospital for Special Surgery (3) The New York Stem Cell Foundation (4) Roswell Park Cancer Institute *PHARMACEUTICAL/TECHNOLOGY MEMBERS: (1) International Business Machines (IBM) *OTHER MEMBERS - NONE ORGANIZATION MEMBERS - DECISION MAKING FORM 990, PART VI, SECTION A, LINE 7A & 7B: EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON THE BOARD OF DIRECTORS. THE EXECUTIVE DIRECTOR ALSO SERVES ON THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE the admission of additional Members, any change to the Mission, Certificate of Incorporation, and Bylaws, etc. The Board also reviews and approves the annual operating budget. Management reserves the ability to enter into business arrangements and contracts, including financing arrangements. FORM 990 REVIEW FORM 990, PART VI, SECTION B, LINE 11: THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT 990, MANAGEMENT (VP OF FINANCE, GENERAL COUNSEL, AND PRESIDENT) WILL REVIEW THE 990.PRIOR TO FILING, MANAGEMENT WILL PRESENT THE 990 TO THE FINANCE AND AUDIT COMMITTEE. ALSO PRIOR TO FILING, MANAGEMENT WILL PROVIDE THE 990 TO THE BOARD OF DIRECTORS. CONFLICT OF INTEREST POLICY & REVIEW FORM 990, PART VI, SECTION B, LINE 12C: NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, PRINCIPAL OFFICERS, OR MEMBERS OF A COMMITTEE IN WHICH THE BOARD HAS DELEGATED POWERS) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY, COMMENCING WITH DECEMBER 2013. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY MAKE A PRESENTATION AT THE BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT RESULTS IN THE CONFLICT OF INTEREST. WHISTLEBLOWER POLICY FORM 990, PART VI, SECTION B, LINE 13: THE ORGANIZATION'S GOVERNING BODY ADOPTED A WRITTEN WHISTLEBLOWER POLICY IN 2015. COMPENSATION REVIEW FORM 990, PART VI, SECTION B, LINE 15: In 2015, the compensation paid to NYGCs senior leadership, including the President and Founding Scientific Director, was reviewed and approved by an executive compensation committee. The members of this committee were independent members of NYGCs board of directors. The committee obtained comparability data from an independent third-party provider (Radford Surveys) for all of the senior leadership positions, and relied on this information in determining the reasonableness of 2015 compensation. The committee documented its decisions regarding 2015 compensation in writing. DOCUMENT DISCLOSURE FORM 990, PART VI, SECTION C, LINE 19: THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.